Dexcom stock plunged Friday after the company raised its sales outlook for the year, but not enough to satisfy investors.
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.